SEVIKAR 40/5 Price

Overview

Welcome to Dwaey, specifically on SEVIKAR 40/5 Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Amlodipine (as besilate), Olmesartan medoxomil.
SEVIKAR 40/5 is available in the market in concentration 5mg, 40mg/Tablet and in the form of Tablets/Film-coated.

SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO. LTD (SAJA) is the producer of SEVIKAR 40/5 and it is imported from KSA, The most popular alternatives of SEVIKAR 40/5 are listed downward .

Mode Of Action

Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina. Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Indication

• Hypertension

Precaution

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal & hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: It is not known whether the amlodipine or olmesartan are excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Side Effects

• >10% Peripheral edema (11%) Frequency Not Defined Palpitation
• Nocturia
• Urinary frequency
• Orthostatic hypotension
• Pruritus
• Rash Potentially Fatal: Acute renal failure.

Contra indication

Pregnancy; biliary obstruction.

Pregnancy and lactation

Pregnancy category: C+D

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters).